United States Patent 10,131,667: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
United States Patent 10,131,667, titled "Substituted tricyclic compounds as FGFR inhibitors," is a significant patent in the pharmaceutical industry, particularly in the treatment of cancers associated with Fibroblast Growth Factor Receptors (FGFR). This patent, assigned to Incyte Corporation, protects a class of tricyclic compounds and their pharmaceutical compositions. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Patent Overview
Patent Title and Number
- Patent Title: Substituted tricyclic compounds as FGFR inhibitors
- Patent Number: US10,131,667B2
- Issue Date: November 20, 2018[4][5].
Inventors and Assignee
- Inventors: Wu Liangxing, Zhang Colin, He Chunhong, Lu Liang, and Yao Wenqing
- Assignee: Incyte Corporation[4][5].
Scope of the Patent
Technical Field
The patent pertains to the field of pharmaceuticals, specifically to tricyclic compounds that act as inhibitors of one or more FGFR enzymes. These compounds are useful in the treatment of FGFR-associated diseases, such as various types of cancer[4][5].
Description of the Invention
The patent describes a class of substituted tricyclic compounds and their pharmaceutical compositions. These compounds are designed to inhibit the activity of FGFR enzymes, which are implicated in the progression of certain cancers. The invention includes detailed descriptions of the chemical structures of these compounds, methods for their synthesis, and their use in treating FGFR-related diseases[4].
Claims of the Patent
Independent Claims
The patent includes several independent claims that define the scope of the invention. These claims typically cover the specific chemical structures of the tricyclic compounds, their pharmaceutical compositions, and methods for using these compounds to treat FGFR-associated diseases.
- Claim 1: A compound of a specific tricyclic structure, which is an inhibitor of one or more FGFR enzymes.
- Claim 2: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: A method for treating an FGFR-associated disease, comprising administering the pharmaceutical composition of claim 2 to a patient in need thereof[4].
Dependent Claims
Dependent claims further narrow down the scope by specifying particular aspects of the independent claims, such as specific substituents on the tricyclic ring, dosage forms, and methods of administration.
Patent Landscape
Related Patents
The patent landscape for FGFR inhibitors includes several other patents filed by Incyte Corporation, which protect various aspects of these compounds and their uses.
- US9,611,267: Another patent by the same inventors, covering similar tricyclic compounds and their use as FGFR inhibitors, with an expiration date of January 30, 2035[2][5].
- US11,466,004: This patent covers solid forms of the FGFR inhibitors and processes for preparing them, with an expiration date of May 3, 2039[2][5].
- US11,628,162: This patent pertains to methods of treating cancer with an FGFR inhibitor, with an expiration date of August 30, 2040[2][5].
Patent Expiration Dates
The expiration dates of these patents are crucial for understanding the timeline of exclusivity for Incyte Corporation.
- US10,131,667: Expires on June 12, 2033[5].
- US9,611,267: Expires on January 30, 2035[5].
- US11,466,004: Expires on May 3, 2039[5].
- US11,628,162: Expires on August 30, 2040[5].
Generic Availability
As of now, there is no generic version of Pemazyre, the drug protected by these patents, available in the United States. The absence of generic alternatives ensures that Incyte Corporation maintains market exclusivity until the patents expire[5].
Search and Analysis Tools
For conducting a thorough analysis of this patent and its landscape, several tools are available:
- Patent Public Search: A web-based tool provided by the USPTO that offers enhanced access to prior art and patent documentation[1].
- Global Dossier: A service that provides access to file histories of related applications from participating IP Offices, including the IP5 Offices[1].
- Common Citation Document (CCD): This tool consolidates prior art citations from multiple offices, facilitating a comprehensive view of the patent family[1].
Impact on Innovation and Competition
The scope and claims of US10,131,667, along with the broader patent landscape, have significant implications for innovation and competition in the pharmaceutical industry.
- Innovation: The patent protects a specific class of compounds, which can incentivize further research and development within Incyte Corporation and other companies, as they seek to develop new and non-infringing compounds.
- Competition: The exclusivity provided by these patents limits competition until they expire, allowing Incyte Corporation to maintain a market monopoly on Pemazyre and related treatments[3].
Metrics for Measuring Patent Scope
Research has shown that metrics such as independent claim length and independent claim count can be used to measure patent scope. Narrower claims at publication are associated with a higher probability of grant and a shorter examination process, indicating the importance of precise claim drafting[3].
Conclusion
United States Patent 10,131,667 is a critical component of Incyte Corporation's intellectual property portfolio, protecting key tricyclic compounds used as FGFR inhibitors. Understanding the scope, claims, and expiration dates of this patent, along with the broader patent landscape, is essential for both the company and its competitors. This analysis highlights the importance of patent search tools, the impact on innovation and competition, and the metrics used to measure patent scope.
Key Takeaways
- Patent Scope: The patent covers specific tricyclic compounds and their pharmaceutical compositions as FGFR inhibitors.
- Claims: Independent and dependent claims define the scope of the invention, including chemical structures, compositions, and methods of use.
- Patent Landscape: Related patents protect various aspects of FGFR inhibitors, with different expiration dates.
- Exclusivity: The absence of generic alternatives ensures Incyte Corporation’s market exclusivity until the patents expire.
- Impact on Innovation and Competition: The patent incentivizes further research and limits competition until its expiration.
FAQs
What is the main subject of United States Patent 10,131,667?
The main subject is substituted tricyclic compounds that act as inhibitors of one or more FGFR enzymes, useful in treating FGFR-associated diseases such as cancer.
Who are the inventors of US10,131,667?
The inventors are Wu Liangxing, Zhang Colin, He Chunhong, Lu Liang, and Yao Wenqing.
What is the expiration date of US10,131,667?
The patent expires on June 12, 2033.
Are there any generic versions of Pemazyre available?
No, there are currently no generic versions of Pemazyre available in the United States.
What tools can be used to conduct a thorough analysis of this patent?
Tools such as Patent Public Search, Global Dossier, and Common Citation Document (CCD) can be used for a comprehensive analysis.
Sources
- USPTO - Search for patents: https://www.uspto.gov/patents/search
- Pharsight - Pemazyre patent expiration: https://pharsight.greyb.com/drug/pemazyre-patent-expiration
- SSRN - Patent Claims and Patent Scope: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2844964
- Google Patents - US10131667B2: https://patents.google.com/patent/US10131667B2/en
- Drugs.com - Generic Pemazyre Availability: https://www.drugs.com/availability/generic-pemazyre.html
